Janet Woodcock, Paul Kim join Friends’ board of directors

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.

NCI Cancer Information Highlights bulletin cut due to RIFs

NCI’s Cancer Information Highlights bulletin, a section of NCI’s Weekly Digest Bulletin that informs readers of research updates related to cancer causes, prevention, screening, treatment, and coping, will no longer be published due to restructuring and reductions in force at HHS.

May 23, 2025

Vol.51 No.20

Cancer Policy

FDA Commissioner Makary holds roundtable discussion on harms of talc

FDA Commissioner Marty Makary held a roundtable of independent scientific experts to discuss the safety and necessity of talc as an additive to food, drugs, and cosmetic products.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter

Cancer Policy

Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access

FDA—under the leadership of cyber-iconoclast and new director of the agency’s Center for Biologics Evaluation and Research, Vinay Prasad—is taking a new approach to COVID-19 vaccines.

May 23, 2025

Vol.51 No.20

By Claire Marie Porter

In Brief

CPRIT awards more than $93M for cancer research and prevention

On May 21, the governing body of the Cancer Prevention and Research Institute of Texas approved 61 grants totaling more than $93 million. The grants support cancer research and prevention projects across the entire spectrum of CPRIT’s mission, including CPRIT Scholar recruitment grants, a wide array of evidence-based prevention programs, and funding for early-stage companies developing promising new treatments for cancer.

May 23, 2025

Vol.51 No.20

Funding Opportunities

DOD prostate cancer research program FY25 funding opportunities

The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Prostate Cancer Research Program. The FY25 PCRP intends to support innovative, high-impact prostate cancer research.

May 23, 2025

Vol.51 No.20

Janet Woodcock, Paul Kim join Friends’ board of directors

YOU MAY BE INTERESTED IN

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

NCI Cancer Information Highlights bulletin cut due to RIFs

FDA Commissioner Makary holds roundtable discussion on harms of talc

Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access

CPRIT awards more than $93M for cancer research and prevention

DOD prostate cancer research program FY25 funding opportunities

Renew today!

Subscriber content

Never miss an issue!

Login